2025
Common Cryoneurolysis Targets in Pain Management: Indications, Critical Anatomy, and Potential Complications
Sailer A, Latich I, Levey A. Common Cryoneurolysis Targets in Pain Management: Indications, Critical Anatomy, and Potential Complications. Seminars In Interventional Radiology 2025, 42: 205-212. PMCID: PMC12077947, DOI: 10.1055/s-0045-1804492.Peer-Reviewed Original ResearchQuality of lifePain managementCombination of therapiesImprove quality of lifeIncreased healthcare costsOpioid consumptionAdjunctive therapyHealthcare costsPatient's painUncontrolled painPhysical sufferingPainPotential complicationsAnatomical considerationsCryoneurolysisAbstract PainImprove qualityPatient outcomesPatientsClinical settingPerson's abilityCritical anatomyPatient pathologyTherapyPersonsScientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence
Olaghere J, Williams D, Farrar J, Büning H, Calhoun C, Ho T, Inamdar M, Liu D, Makani J, Nyarko K, Ruiz S, Tisdale J, McCune J, Boadi E, for the FDA R. Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence. Biomedicines 2025, 13: 758. PMID: 40149734, PMCID: PMC11940732, DOI: 10.3390/biomedicines13030758.Peer-Reviewed Original ResearchFood and Drug AdministrationGene therapySickle cell diseaseFDA-approved therapiesCost of therapyRegulatory convergenceGates FoundationCell diseaseTherapyDrug AdministrationMiddle-income countriesGlobal health advocatesModel disorderRegulatory gapsInternational regulatory bodiesReagan-Udall FoundationRegulated industriesGenesRegulatory bodiesCorticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance
Konkle B, Peyvandi F, Foster G, Hermans C, La Mura V, Leavitt A, Lillicrap D, Mahlangu J, Ozelo M, Pipe S, Recht M, Srivastava A, Young G, Miesbach W. Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance. Journal Of Thrombosis And Haemostasis 2025 PMID: 40090623, DOI: 10.1016/j.jtha.2025.02.042.Peer-Reviewed Original ResearchSevere hemophilia AValoctocogene roxaparvovecFactor VIIIGene therapyHemophilia AMarkers of hepatocyte injuryFactor VIII activity levelsCourse of corticosteroidsFactor VIII levelsElevated alanine transaminaseReduced FVIII levelsClinical practice guidanceFVIII levelsCorticosteroid useAdverse eventsClinical dataClinical trialsCorticosteroidsHepatocyte injuryAlanine transaminaseTherapyPatientsActivity levelsExpert opinionAdultsAssociations between interpersonal synchrony and clients’ perception of session quality are moderated by depression severity
Stolowicz-Melman D, Atzil-Slonim D, Paz A, Bar-Kalifa E, Gilboa-Schechtman E, Feldman R. Associations between interpersonal synchrony and clients’ perception of session quality are moderated by depression severity. Psychotherapy Research 2025, ahead-of-print: 1-11. PMID: 40049158, DOI: 10.1080/10503307.2025.2462150.Peer-Reviewed Original ResearchSystemic Therapies for Pediatric Alopecia Areata
Kalil L, Welch D, Heath C, Craiglow B. Systemic Therapies for Pediatric Alopecia Areata. Pediatric Dermatology 2025, 42: 36-42. PMID: 40044621, DOI: 10.1111/pde.15822.Peer-Reviewed Original ResearchConceptsAlopecia areataSystemic therapyPediatric alopecia areataAutoimmune hair loss disorderJanus kinase inhibitorsHair loss disorderComorbid atopyOral minoxidilLong-term useSystemic corticosteroidsTopical therapySystemic treatmentPediatric AACase reportAdjunctive treatmentMild diseaseKinase inhibitorsImmunomodulatory medicinesTherapyExtensive involvementAdverse effectsNarrative reviewAreataPatientsTreatmentDeterminants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Callari M, Dugo M, Barreca M, Győrffy B, Galbardi B, Vigano L, Locatelli A, Dall’Ara C, Ferrarini M, Bisagni G, Colleoni M, Mansutti M, Zamagni C, Del Mastro L, Zambelli S, Frassoldati A, Biasi O, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies. Nature Communications 2025, 16: 2195. PMID: 40038334, PMCID: PMC11880565, DOI: 10.1038/s41467-025-57293-9.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesBreast cancerEndocrine therapyImmune infiltrationPrediction of pCRAnti-HER2 therapyLuminal A phenotypeHigher immune infiltrationFemale breast cancerHER2 blockadeDeterminants of responseTumor responseInfiltrating lymphocytesCDK4/6 inhibitionAnti-HER2HER2 targetingClinical endpointsER signalingKi67Response groupCancerTherapyTherapeutic targetMolecular changesTumorAcceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study
Chayama K, Ng C, Brohman I, Mansoor M, Small W, Philbin M, Collins A, McNeil R. Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study. PLOS ONE 2025, 20: e0319010. PMID: 40019916, PMCID: PMC11870339, DOI: 10.1371/journal.pone.0319010.Peer-Reviewed Original ResearchConceptsAdherence to antiretroviral therapyLong-acting antiretroviral therapyLA-ARTAntiretroviral therapySuboptimal adherence to antiretroviral therapyAdherence barriersProspective cohort studySuboptimal ART adherenceAdverse side effectsPill burdenTreatment optionsSubstance useCohort studyART adherenceTreatment advancesSide effectsTreatment changesPLHIVTreatment approachesTherapyCredible sources of informationPopulation-level benefitsDrugHIVSocial-structural inequitiesAdvancing drug development in myelodysplastic syndromes
Mina A, McGraw K, Cunningham L, Kim N, Jen E, Calvo K, Ehrlich L, Aplan P, Garcia-Manero G, Foran J, Garcia J, Zeidan A, DeZern A, Komrokji R, Sekeres M, Scott B, Buckstein R, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic S, Norsworthy K. Advancing drug development in myelodysplastic syndromes. Blood Advances 2025, 9: 1095-1104. PMID: 39786387, PMCID: PMC11914162, DOI: 10.1182/bloodadvances.2024014865.Peer-Reviewed Original ResearchConceptsAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationEnd pointsStem cell malignanciesTime-to-event end pointsStem cell transplantationUS Food and Drug AdministrationTreatment of patientsFood and Drug AdministrationClinical trial designDrug developmentMyelodysplastic syndromeCell transplantationCurative therapyRisk stratificationPoor prognosisCell malignancyTransformative therapiesDrug AdministrationBiomarker developmentResponse definitionsTrial designFunctional assessmentTherapyPatientsMoving beyond desensitization to tolerance in food allergy
Flom J, Shreffler W, Perrett K. Moving beyond desensitization to tolerance in food allergy. The Journal Of Allergy And Clinical Immunology In Practice 2025 PMID: 40010566, DOI: 10.1016/j.jaip.2025.02.014.Peer-Reviewed Original ResearchManagement of IgE-mediated food allergyFood allergyIgE-mediated food allergyStages of clinical developmentSide effect profileMode of deliveryGoal of therapeuticsSustained unresponsivenessDosing regimensDose protocolProactive therapyAllergen-specificClinical developmentActive therapyPatient populationSide effectsTherapyPassive therapyPatient-specificDesensitizationClinical contextPatientsDoseAllergyDegree of protectionAssociation between guideline-directed medical therapy and reintervention risk following peripheral vascular interventions in patients with peripheral artery disease.
Callegari S, Romain G, Capuano I, Cleman J, Scierka L, Smolderen K, Mena-Hurtado C. Association between guideline-directed medical therapy and reintervention risk following peripheral vascular interventions in patients with peripheral artery disease. Vascular Medicine 2025, 1358863x251320347. PMID: 39992181, DOI: 10.1177/1358863x251320347.Peer-Reviewed Original ResearchGuideline-directed medical therapyGuideline-directed medical therapy ratesPeripheral vascular interventionsPeripheral arterial diseaseReintervention outcomesReintervention riskMedical therapyArtery diseaseVascular interventionsAngiotensin receptor blockersCompeting risk analysisScore-matched cohortReceipt of statinsPost-PVIAngiotensin-converting enzymeReceptor blockersReinterventionMedicare outcomesMedication adherencePatientsRegistry dataTherapyOutcomesReceiptRiskA roadmap for uniform comprehensive long- term follow up after curative therapy for sickle cell disease
Shenoy S, Kanter J, Kassim A, Fitzhugh C, Stenger E, Bhatia M, Pecker L, Krishnamurti L, King A. A roadmap for uniform comprehensive long- term follow up after curative therapy for sickle cell disease. Blood Advances 2025 PMID: 39993235, DOI: 10.1182/bloodadvances.2024013953.Peer-Reviewed Original ResearchPericardial Disease: Contemporary Techniques and Management
Bae J, Saleh A, Hu J, Setaro J, Altin S. Pericardial Disease: Contemporary Techniques and Management. Current Treatment Options In Cardiovascular Medicine 2025, 27: 23. DOI: 10.1007/s11936-025-01081-7.Peer-Reviewed Original ResearchTreatment of recurrent pericarditisManagement of pericardial diseasesImmunosuppressive therapyRecurrent pericarditisTransthoracic echocardiographySignificant management challengeRefractory casesRecurrence ratePericardial diseaseTherapeutic optionsPharmacological therapyTherapeutic advancesClinical trialsTherapeutic approachesPoor visualizationDiagnostic precisionTherapyPatientsDiseaseDiagnostic techniquesSymptom burdenEvidence-basedPatient careTransthoracicEchocardiographyUS Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or CAR T- cell therapy: An ASTCT Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines
Munshi P, Olin R, Wall S, McCurdy S, Al-Juhaishi T, Baker J, Bhatt V, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton B, Inamoto Y, Jayani R, Kharfan-Dabaja M, Lin R, Meyers G, Mishra A, Murthy H, Nawas M, Rosko A, Ruiz M, Sorror M, Sung A, Carpenter P, Hamadani M, Artz A. US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or CAR T- cell therapy: An ASTCT Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplantation And Cellular Therapy 2025 PMID: 39961473, DOI: 10.1016/j.jtct.2025.02.014.Peer-Reviewed Original ResearchHematopoietic cell transplantationT-cell therapyCAR-T cell therapyCAR-TCell transplantationGeriatric assessmentCellular therapyChimeric antigen T-cell therapyAmerican Society for TransplantationPromote risk stratificationAllo-HCTRisk stratificationCell therapyOlder patientsRoutine GAOlder adultsGa uptakeTherapyPhysician practice patternsTransplantationPractice patternsClinical support staffCross-sectional surveyPhysician membersDomain of GAComparative analysis of AAV serotypes for transduction of olfactory sensory neurons
Belfort B, Jia J, Garza A, Insalaco A, McGinnis J, Pekarek B, Ortiz-Guzman J, Tepe B, Chen H, Investigators A, Liu Z, Arenkiel B, Arenkiel B, Liu Z, Mollenhauer B, Penninger J, Rousseaux M, Saghatelyan A, Salmaso N, Stadelmann C, Schlossmacher M, Tomlinson J, Woulfe J, Wang Y, Chen Z, Jeong M. Comparative analysis of AAV serotypes for transduction of olfactory sensory neurons. Frontiers In Neuroscience 2025, 19: 1531122. PMID: 40018362, PMCID: PMC11865030, DOI: 10.3389/fnins.2025.1531122.Peer-Reviewed Original ResearchOlfactory sensory neuronsAAV serotypesSensory neuronsCentral nervous systemOptimal AAV serotypeAdeno-associated virusNervous systemGene therapyNasal inoculationSingle-nucleus RNA sequencingOdor informationNeuronal biologyNeuronsModel diseaseSerotypesConfocal imagingVolatile odorantsRNA sequencingSensory inputAAV1AAVSingle-nucleusTransductionTherapyTropismComputational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, Dutta J, El-Fakhri G, McMeekin H, Pandit-Taskar N, Schwartz J, Shi K, Strigari L, Zaidi H, Saboury B, Rahmim A. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories. Journal Of Nuclear Medicine 2025, jnumed.124.267927. PMID: 39947910, DOI: 10.2967/jnumed.124.267927.Peer-Reviewed Original ResearchRadiopharmaceutical therapyImage-based dosimetryPrediction of doseInternal dosimetryPersonalized treatment plansMetastatic diseaseDosimetryNuclear oncologyClinical outcomesNuclear medicineClinical endpointsTreatment planningOncology communityDose responseEtiological mechanismsTargeted deliveryRadiobiologyRadiotherapyMalignancyRadiationLong-termTherapyPharmacotherapyDoseRadiopharmacokineticsInvestigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis
Spagnolo P, Tonelli R, Mura M, Reisman W, Sotiropoulou V, Tzouvelekis A. Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis. Expert Opinion On Investigational Drugs 2025, 34: 61-80. PMID: 39916340, DOI: 10.1080/13543784.2025.2462592.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisGene therapyPulmonary fibrosisAssociated with tolerability issuesProgressive fibrosing interstitial lung diseaseEfficacy of gene therapyApplication of gene therapyTreatment of idiopathic pulmonary fibrosisLong-term clinical dataFibrosing interstitial lung diseaseFirst-line therapyImproved vector designInterstitial lung diseaseMitigate off-target effectsTolerated treatmentDismal prognosisClinical dataLung diseaseClinical studiesAssociated with poor qualityProfibrotic pathwaysTarget cellsTherapyFibrosisOff-target effectsSerial Lactate in Clinical Medicine - A Narrative Review.
Falter F, Tisherman S, Perrino A, Kumar A, Bush S, Nordström L, Pathan N, Liu R, Mebazaa A. Serial Lactate in Clinical Medicine - A Narrative Review. Journal Of Intensive Care Medicine 2025, 8850666241303460. PMID: 39925111, DOI: 10.1177/08850666241303460.Peer-Reviewed Original ResearchResponse to therapyWarning ScoreAcute clinical areasHospital IT systemsElectronic patient recordsPoint of careNursing workforceClinical medicineDeteriorating patientsClinical areasSerial lactateMultidisciplinary groupHospital areasPrognostic guidePatient recordsLactate clearanceTreatment decisionsClinical utilityIntensive careEmergency roomPatient statusLactate levelsDisciplines of clinical medicineTherapyOperating roomApproach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America.
Chalker C, Ong M, McKay R, Tangen C, Gulati S, Keim M, Lerner S, Dorff T, Sokolova A. Approach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America. Journal Of Clinical Oncology 2025, 43: 263-263. DOI: 10.1200/jco.2025.43.5_suppl.263.Peer-Reviewed Original ResearchProstate specific antigenTriplet therapyDoublet therapyGenitourinary oncologistsPatient comorbiditiesClinical trialsVolume of diseaseClinical Trials GroupOptimal clinical settingClinical trial enrollmentRandomized clinical trialsDe novoMHSPC patientsApproach to treatmentDisease volumeSystemic therapyTriple therapyYears of clinical experienceMHSPCSpecific antigenClinician specialtyPatient factorsTrial enrollmentTherapyPatientsSurgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar A, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Hematology/Oncology Clinics Of North America 2025, 39: 25-35. PMID: 39510675, DOI: 10.1016/j.hoc.2024.08.012.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesSystemic chemotherapyHepatic resectionAblation therapyIsolated breast cancer liver metastasesLong-term outcomes of womenProlonged disease-free intervalLocal-regional therapyCancer liver metastasesDisease-free intervalOutcomes of womenBreast cancer metastasisLong-term outcomesRegional therapyLiver metastasesOverall survivalSurgery benefitMultidisciplinary settingCancer metastasisPatientsResectionChemotherapyMetastasisTherapySurgeryStructural Brain Changes Associated With Cognitive Behavioral Therapy in Cocaine Use Disorder Treatment
McCurdy L, DeVito E, Loya J, Nich C, Kiluk B, Potenza M. Structural Brain Changes Associated With Cognitive Behavioral Therapy in Cocaine Use Disorder Treatment. Drug And Alcohol Dependence 2025, 267: 112224. DOI: 10.1016/j.drugalcdep.2024.112224.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply